vs
ANI PHARMACEUTICALS INC（ANIP）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是BRC Group Holdings, Inc.的1.3倍（$247.1M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 11.1%，领先36.8%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -21.9%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -15.4%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
ANIP vs RILY — 直观对比
营收规模更大
ANIP
是对方的1.3倍
$188.3M
营收增速更快
ANIP
高出51.5%
-21.9%
净利率更高
RILY
高出36.8%
11.1%
两年增速更快
ANIP
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $188.3M |
| 净利润 | $27.5M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 14.1% | 32.3% |
| 净利率 | 11.1% | 47.9% |
| 营收同比 | 29.6% | -21.9% |
| 净利润同比 | 367.5% | 1710.8% |
| 每股收益（稀释后） | $1.14 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRILY
| Q4 25 | $247.1M | $188.3M | ||
| Q3 25 | $227.8M | $215.3M | ||
| Q2 25 | $211.4M | $188.2M | ||
| Q1 25 | $197.1M | $197.2M | ||
| Q4 24 | $190.6M | $241.0M | ||
| Q3 24 | $148.3M | $225.5M | ||
| Q2 24 | $138.0M | $256.0M | ||
| Q1 24 | $137.4M | $263.4M |
净利润ANIPRILY
| Q4 25 | $27.5M | $90.3M | ||
| Q3 25 | $26.6M | $91.1M | ||
| Q2 25 | $8.5M | $139.5M | ||
| Q1 25 | $15.7M | $-10.0M | ||
| Q4 24 | $-10.3M | $-5.6M | ||
| Q3 24 | $-24.2M | $-284.4M | ||
| Q2 24 | $-2.3M | $-433.6M | ||
| Q1 24 | $18.2M | $-49.2M |
毛利率ANIPRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率ANIPRILY
| Q4 25 | 14.1% | 32.3% | ||
| Q3 25 | 15.9% | 30.4% | ||
| Q2 25 | 6.6% | 5.7% | ||
| Q1 25 | 13.3% | -31.2% | ||
| Q4 24 | -2.3% | -69.2% | ||
| Q3 24 | -13.8% | -36.4% | ||
| Q2 24 | 3.7% | -90.8% | ||
| Q1 24 | 14.8% | -6.1% |
净利率ANIPRILY
| Q4 25 | 11.1% | 47.9% | ||
| Q3 25 | 11.7% | 42.3% | ||
| Q2 25 | 4.0% | 74.1% | ||
| Q1 25 | 8.0% | -5.1% | ||
| Q4 24 | -5.4% | -2.3% | ||
| Q3 24 | -16.3% | -126.1% | ||
| Q2 24 | -1.7% | -169.4% | ||
| Q1 24 | 13.2% | -18.7% |
每股收益（稀释后）ANIPRILY
| Q4 25 | $1.14 | $2.78 | ||
| Q3 25 | $1.13 | $2.91 | ||
| Q2 25 | $0.36 | $4.50 | ||
| Q1 25 | $0.69 | $-0.39 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $-1.27 | $-9.39 | ||
| Q2 24 | $-0.14 | $-14.35 | ||
| Q1 24 | $0.82 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $540.7M | $-171.5M |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRILY
| Q4 25 | $285.6M | $226.6M | ||
| Q3 25 | $262.6M | $184.2M | ||
| Q2 25 | $217.8M | $267.4M | ||
| Q1 25 | $149.8M | $138.3M | ||
| Q4 24 | $144.9M | $146.9M | ||
| Q3 24 | $145.0M | $159.2M | ||
| Q2 24 | $240.1M | $236.9M | ||
| Q1 24 | $228.6M | $190.7M |
总债务ANIPRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANIPRILY
| Q4 25 | $540.7M | $-171.5M | ||
| Q3 25 | $505.8M | $-260.5M | ||
| Q2 25 | $436.8M | $-351.7M | ||
| Q1 25 | $418.6M | $-496.8M | ||
| Q4 24 | $403.7M | $-488.2M | ||
| Q3 24 | $405.9M | $-497.6M | ||
| Q2 24 | $455.8M | $-218.3M | ||
| Q1 24 | $452.0M | $228.4M |
总资产ANIPRILY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $920.8M | $3.2B | ||
| Q1 24 | $914.5M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPRILY
| Q4 25 | $30.4M | $26.2M | ||
| Q3 25 | $44.1M | $-60.6M | ||
| Q2 25 | $75.8M | $-25.6M | ||
| Q1 25 | $35.0M | $184.0K | ||
| Q4 24 | $15.9M | $-2.7M | ||
| Q3 24 | $12.5M | $19.5M | ||
| Q2 24 | $17.4M | $111.5M | ||
| Q1 24 | $18.3M | $135.4M |
自由现金流ANIPRILY
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPRILY
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPRILY
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPRILY
| Q4 25 | 1.10× | 0.29× | ||
| Q3 25 | 1.66× | -0.66× | ||
| Q2 25 | 8.87× | -0.18× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
